NSE: AJANTPHARM | BSE: 532331

Mid-range Performer

Download real time

2681.60 -52.90 (-1.93%)

55,916 NSE+BSE Volume

High vol. this week

NSE 26 Dec, 2025 3:31 PM (IST)

33,496.4

Market Cap

High in industry

Beta 1Year

Very Low volatility

Signs Agreement

Ajanta Pharma signs an agreement with Biocon to market Semaglutide with a market size of $26 bn See details

Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Search Inside the pdf :

Ajanta Pharma Ltd.

04 Nov 2025

2681.60

-1.93%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Q2FY26- Momentum driven by US and India Business - Revenues grew ~14% YoY to 1354 crore driven by US and India branded business which grew ~48% / ~12% to 344 crore and 432 crore, respectively. Other branded businesses such as Asia and Africa witnessed the growth of 5% / 4% (on higher base) to 310 crore and 221 crore, respectively. On the operational front, EBITDA grew 5.4% YoY to ~328 crore (excluding forex losses of 41 crore, 9 % growth to ~369 crore) with margins at 24.2%...

Ajanta Pharma Ltd. has an average target of 2939.17 from 6 brokers.

Ajanta Pharma Ltd.

03 Nov 2025

2681.60

-1.93%

In-line 2Q; growth led by DF/US generics

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP)’s 2QFY26 revenue was slightly above our expectation (3.5% beat). EBITDA and PAT were largely in line and grew at a lower rate compared to revenue growth for the quarter.

Ajanta Pharma Ltd. is trading above all available SMAs

Ajanta Pharma Ltd.

19 Sep 2025

2681.60

-1.93%

Ajanta Pharma (AJP IN) Company Initiation Leveraging BGx...

Buy: Ajanta Pharma Ltd.

Prabhudas Lilladhar

Promoters pledged 1.16% of shares in last quarter. Total pledge stands at 15.28% of promoter holdings

Ajanta Pharma Ltd.

16 Jun 2025

2681.60

-1.93%

BP Equities Ajanta Pharma Ltd. Shining Star Series BUY Target 3,140

Buy: Ajanta Pharma Ltd.

BP Wealth

Ajanta Pharma Ltd. is trading above all available SMAs

Ajanta Pharma Ltd.

01 May 2025

2681.60

-1.93%

Ajanta Pharma (HOLD): A New Dawn of Culture

Hold: Ajanta Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Mix set of earnings where sales/EBITDA/PAT reported 5%/3%/10% above estimates; EBITDA margin reported 60 bps below estimates

Ajanta Pharma Ltd. has an average target of 2939.17 from 6 brokers.

Ajanta Pharma Ltd.

01 May 2025

2681.60

-1.93%

Elevated cost to keep a check on margins

Sell: Ajanta Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Ajanta Pharma’s Q4FY25 result was in line with our expectations. Revenue growth of 11% YoY was primarily driven by India and US businesses while Africa institutional biz continues to be a drag (-54.1% YoY).

Ajanta Pharma Ltd. average weekly volume is high.

Ajanta Pharma Ltd.

31 Jan 2025

2681.60

-1.93%

Ajanta Pharma (SELL): Entering newer therapies to result in higher costs

Sell: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

AJP reported in-line earnings, sales were 3.6% below estimates, while EBITDA/PAT reported 1%/3% above our estimates

Ajanta Pharma Ltd. average weekly volume is high.

Ajanta Pharma Ltd.

30 Jan 2025

2681.60

-1.93%

India/Asia drive earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered a marginally better-than-expected performance in 3QFY25. It has continued to outperform in the Domestic Formulation (DF) market during this quarter.